Anteris Technologies Global (NASDAQ:AVR) Stock: Insider L1 Capital Pty Ltd Buys 272,695 Shares

Anteris Technologies Global Corp. (NASDAQ:AVR) major shareholder L1 Capital Pty Ltd acquired 272,695 shares of the business’s stock in a transaction on Tuesday, October 6th. The shares were purchased at an average price of $7.18 per share, for a total transaction of $1,957,950.10. Following the transaction, the insider directly owned 6,358,271 shares of the company’s stock, valued at approximately $45,652,385.78. The trade was a 4.48% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

L1 Capital Pty Ltd also recently made the following trade(s):

• On Monday, October 5th, L1 Capital Pty Ltd bought 648,455 shares of Anteris Technologies Global stock. The stock was bought at an average price of $7.51 per share, for a total transaction of $4,869,897.05.
• On Friday, October 2nd, L1 Capital Pty Ltd purchased 236,354 shares of Anteris Technologies Global stock. The stock was purchased at an average price of $7.78 per share, with a total value of $1,838,834.12.
• On Thursday, October 1st, L1 Capital Pty Ltd bought 322,940 shares of Anteris Technologies Global stock. The shares were acquired at an average cost of $7.60 per share, for a total transaction of $2,454,344.00.
• On Wednesday, September 30th, L1 Capital Pty Ltd bought 74,286 shares of Anteris Technologies Global stock. The stock was bought at an average price of $7.72 per share, for a total transaction of $573,487.92.
• On Friday, August 28th, L1 Capital Pty Ltd sold 7,800 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.83, for a total transaction of $68,874.00.
• On Tuesday, August 11th, L1 Capital Pty Ltd sold 375,815 shares of Anteris Technologies Global stock. The stock was sold at an average price of $9.30, for a total transaction of $3,495,079.50.
• On Monday, August 10th, L1 Capital Pty Ltd sold 251,844 shares of Anteris Technologies Global stock. The stock was sold at an average price of $9.10, for a total transaction of $2,291,780.40.
• On Thursday, August 6th, L1 Capital Pty Ltd sold 174,721 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.10, for a total value of $1,415,240.10.
• On Tuesday, August 4th, L1 Capital Pty Ltd sold 480,608 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.30, for a total transaction of $3,989,046.40.
• On Wednesday, August 5th, L1 Capital Pty Ltd sold 14,581 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.23, for a total transaction of $120,001.63.

Anteris Technologies Global Stock Down 2.8%

Shares of NASDAQ:AVR traded down $0.19 during trading on Thursday, hitting $6.63. The stock had a trading volume of 2,470,247 shares, compared to its average volume of 1,098,027. Anteris Technologies Global Corp. has a 12-month low of $3.30 and a 12-month high of $11.06. The stock has a market capitalization of $646.16 million, a price-to-earnings ratio of -3.40 and a beta of 1.87. The stock has a 50-day simple moving average of $8.41 and a two-hundred day simple moving average of $8.03.

Anteris Technologies Global (NASDAQ:AVR) last issued its earnings results on Tuesday, August 11th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.09). Anteris Technologies Global had a negative net margin of 4,619.27% and a negative return on equity of 77.69%. The firm had revenue of $1.01 million during the quarter, compared to analysts’ expectations of $1.50 million. During the same quarter in the prior year, the company earned ($0.58) EPS. As a group, sell-side analysts forecast that Anteris Technologies Global Corp. will post -1.21 earnings per share for the current year.

Analyst Upgrades and Downgrades

AVR has been the topic of several research analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $15.00 price objective on shares of Anteris Technologies Global in a report on Friday, August 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Anteris Technologies Global in a research report on Wednesday, August 26th. Finally, Barclays upgraded Anteris Technologies Global to a “hold” rating in a research report on Wednesday. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $14.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Cetera Investment Advisers boosted its holdings in Anteris Technologies Global by 64.7% in the 1st quarter. Cetera Investment Advisers now owns 16,550 shares of the company’s stock worth $92,000 after buying an additional 6,500 shares during the last quarter. Bank of America Corp DE raised its stake in Anteris Technologies Global by 12.6% in the 1st quarter. Bank of America Corp DE now owns 68,755 shares of the company’s stock valued at $382,000 after purchasing an additional 7,688 shares during the last quarter. Legal & General Group Plc acquired a new stake in Anteris Technologies Global during the 2nd quarter worth $78,000. Bartlett & CO. Wealth Management LLC grew its holdings in shares of Anteris Technologies Global by 174.5% during the first quarter. Bartlett & CO. Wealth Management LLC now owns 12,900 shares of the company’s stock worth $79,000 after buying an additional 8,200 shares in the last quarter. Finally, Abel Hall LLC acquired a new stake in shares of Anteris Technologies Global in the first quarter valued at about $63,000.

About Anteris Technologies Global

Anteris Technologies Global is a clinical-stage structural heart company developing technologies intended to treat aortic valve disease. The company’s lead product is the DurAVR transcatheter heart valve, which is designed to replicate the performance characteristics of a healthy human aortic valve and restore more natural blood flow.

Anteris uses its proprietary ADAPT tissue-engineering technology to create heart-valve materials designed for durability and biocompatibility. The company is focused primarily on transcatheter aortic valve replacement and related structural-heart applications, with its products progressing through clinical development and regulatory evaluation rather than broad commercial distribution.

The company has Australian origins and maintains operations and clinical-development activities in both Australia and the United States.